COVID-19: benefits and risks of passive immunotherapeutics

Passive immunotherapeutics (PITs), including convalescent plasma, serum, or hyperimmune immunoglobulin, have been of clinical importance during sudden outbreaks since the early twentieth century for the treatment of viral diseases such as severe acute respiratory syndrome (SARS), middle east respira...

Full description

Bibliographic Details
Published in:Human Vaccines & Immunotherapeutics
Main Authors: Ankur Gupta, Rashmi Karki, Himanshu R Dandu, Kuldeep Dhama, Madan LB Bhatt, Shailendra K Saxena
Format: Article
Language:English
Published: Taylor & Francis Group 2020-12-01
Subjects:
covid-19
sars-cov-2
immunotherapeutics
convalescent plasma therapy
hyperimmune immunoglobulin
sars
mers
Online Access:http://dx.doi.org/10.1080/21645515.2020.1808410

Internet

http://dx.doi.org/10.1080/21645515.2020.1808410

Similar Items